Bispecific antibodies specific for treating hematological malignancies
The present disclosure provides compositions and methods for improved pre-targeted radioimmunotherapeutics (PRIT) to treat various hematological disorders, such as B cell hyperproliferative disorders and solid tumors. The disclosed compositions include bispecific antibody compositions having a first domain that specifically bind to an antigen such as CD38, BCMA, Muc1, GPRC5D, or Slam7, and a second domain that specifically binds to a radioactive ligand. Methods include administering the disclosed bispecific antibody reagent and separately administering the radioactive ligand. In some embodiments, a clearing agent is also administered. In some embodiments, the therapeutic methods comprise administering a combination of two or more bispecific antibody reagents. In some embodiments, an enhancing agent, such as ATRA, gamma secretase inhibitor, or dextramethasone, is also administered to enhance expression of the target antigen on the target cells.
1. A bispecific affinity reagent, comprising:
a first binding domain that binds to a CD38 antigen or a B cell maturation antigen (BCMA), wherein the first binding domain that binds to the CD38 antigen comprises an amino acid sequence included in an amino acid sequence of the bispecific affinity reagent as set forth in any one of SEQ ID NOs: 2, 4, or 6, and wherein the first binding domain that binds the BCMA comprises an amino acid sequence included in an amino acid sequence of the bispecific affinity reagent as set forth in any one of SEQ ID NOs: 8 or 10; and
a second binding domain that binds to a yttrium-DOTA (Y-DOTA) ligand, wherein the second binding domain that binds to the Y-DOTA ligand comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 20-36.
2. The bispecific affinity reagent of claim 1 , wherein the affinity reagent is a fusion protein and the first binding domain and the second binding domain are separated by a hinge region.
3. A method of treating a hematological malignancy expressing a CD38 antigen and/or a BCMA in a subject, the method comprising:
administering to the subject a therapeutically effective amount of the bispecific affinity reagent of claim 1 , and thereafter;
administering to the subject a therapeutically effective amount of the Y-DOTA ligand.
4. The method of claim 3 , further comprising administering an effective amount of a clearing agent (CA) after administering the bispecific affinity reagent and before administering the Y-DOTA ligand.
5. The method of claim 3 , further comprising administering to the subject an amount of a gamma secretase inhibitor (GSI) sufficient to upregulate expression of BCMA in the malignant cells.
6. A method of treating a hematological malignancy expressing a CD38 antigen and/or a B cell maturation antigen (BCMA) in a subject, the method comprising:
administering to the subject a therapeutically effective amount of a first bispecific affinity reagent, wherein the first bispecific affinity reagent comprises a first binding domain that binds to a CD38 antigen, and wherein the first binding domain comprises an amino acid sequence included in an amino acid sequence of the bispecific affinity reagent as set forth in any one of SEQ ID NOs: 2, 4, or 6, and a second binding domain that binds to a yttrium-DOTA (Y-DOTA) ligand, wherein the second binding domain that binds to the Y-DOTA ligand comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 20-36;
administering to the subject a therapeutically effective amount of a second bispecific affinity reagent, wherein the second bispecific affinity reagent comprises a first binding domain that binds to the BCMA, and wherein the second binding domain comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 8 or 10, and a second binding domain that binds to a Y-DOTA ligand, wherein the second binding domain that binds to the Y-DOTA ligand comprises an amino acid sequence as set forth in any one of SEQ ID NOs: 20-36 and
thereafter; and administering to the subject a therapeutically effective amount of the Y-DOTA ligand.
7. The method of claim 6 , further comprising administering an effective amount of a clearing agent (CA) after administering the bispecific affinity reagent and before administering the Y-DOTA ligand.